Reduced adenosine receptor expression in ACS patients with no-reflow phenomenon undergoing primary PCI.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Future cardiology Pub Date : 2025-01-01 Epub Date: 2024-12-24 DOI:10.1080/14796678.2024.2445419

Amin Bagheri, Saeed Alipour Parsa, Mohammad Hasan Namazi, Isa Khaheshi, Nasim Sohrabifar

{"title":"Reduced adenosine receptor expression in ACS patients with no-reflow phenomenon undergoing primary PCI.","authors":"Amin Bagheri, Saeed Alipour Parsa, Mohammad Hasan Namazi, Isa Khaheshi, Nasim Sohrabifar","doi":"10.1080/14796678.2024.2445419","DOIUrl":null,"url":null,"abstract":"Introduction: Acute coronary syndrome (ACS) patients undergoing primary percutaneous coronary intervention (PPCI) often experience the no-reflow phenomenon (NRP), characterized by reduced myocardial perfusion despite an open coronary artery. Adenosine, a potent vasodilator, is used to aid reperfusion. To elucidate underlying molecular mechanism of this phenomenon, we investigated expression of ADORA2A and ADORA2B genes, encoding adenosine receptors, in ACS patients with NRP and non-NRP.Methods: We conducted a case-control study of 102 ACS patients undergoing PPCI, including 51 patients with NRP (TIMI flow grade 0 or 1) and 51 non-NRP patients with normal flow (TIMI flow grade 2 or 3). Gene expression was measured using Real-Time PCR.Results: Analysis showed significantly reduced expression of both ADORA2A and ADORA2B genes in NRP patients compared to non-NRP (p < 0.01). Furthermore, we observed a direct and moderate correlation between the two genes in NRP patients (r = 0.45, p = 0.001), whereas the correlation was stronger and more direct in non-NRP (r = 0.8, p = 0.0001).Conclusion: Reduced adenosine receptor expression may contribute to the NRP in ACS patients undergoing PPCI. These findings highlighted the importance of understanding molecular mechanisms underlying this phenomenon to develop targeted therapies aimed at improving cardiac reperfusion.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"23-29"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812326/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2445419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Acute coronary syndrome (ACS) patients undergoing primary percutaneous coronary intervention (PPCI) often experience the no-reflow phenomenon (NRP), characterized by reduced myocardial perfusion despite an open coronary artery. Adenosine, a potent vasodilator, is used to aid reperfusion. To elucidate underlying molecular mechanism of this phenomenon, we investigated expression of ADORA2A and ADORA2B genes, encoding adenosine receptors, in ACS patients with NRP and non-NRP.

Methods: We conducted a case-control study of 102 ACS patients undergoing PPCI, including 51 patients with NRP (TIMI flow grade 0 or 1) and 51 non-NRP patients with normal flow (TIMI flow grade 2 or 3). Gene expression was measured using Real-Time PCR.

Results: Analysis showed significantly reduced expression of both ADORA2A and ADORA2B genes in NRP patients compared to non-NRP (p < 0.01). Furthermore, we observed a direct and moderate correlation between the two genes in NRP patients (r = 0.45, p = 0.001), whereas the correlation was stronger and more direct in non-NRP (r = 0.8, p = 0.0001).

Conclusion: Reduced adenosine receptor expression may contribute to the NRP in ACS patients undergoing PPCI. These findings highlighted the importance of understanding molecular mechanisms underlying this phenomenon to develop targeted therapies aimed at improving cardiac reperfusion.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

无血流现象的ACS患者行首次PCI时腺苷受体表达降低。

简介：急性冠状动脉综合征（ACS）患者在接受原发性经皮冠状动脉介入治疗（PPCI）时，经常出现无回流现象（NRP），其特征是冠状动脉开放，但心肌灌注减少。腺苷是一种有效的血管扩张剂，用于辅助再灌注。为了阐明这一现象的潜在分子机制，我们研究了编码腺苷受体的ADORA2A和ADORA2B基因在ACS合并NRP和非NRP患者中的表达。方法：我们对102例接受PPCI的ACS患者进行了病例对照研究，包括51例NRP患者（TIMI流量等级0或1）和51例非NRP患者（TIMI流量等级2或3）。使用Real-Time PCR检测基因表达。结果：分析显示，与非NRP患者相比，NRP患者中ADORA2A和ADORA2B基因的表达均显著降低（p r = 0.45, p = 0.001），而非NRP患者的相关性更强、更直接（r = 0.8, p = 0.0001）。结论：腺苷受体表达降低可能与ACS患者PPCI后NRP的发生有关。这些发现强调了理解这一现象背后的分子机制对于开发旨在改善心脏再灌注的靶向治疗的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.